Page last updated: 2024-12-06

quinfamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Quinfamide is a synthetic antiprotozoal drug that was developed in the 1960s. It is effective against a variety of protozoan parasites, including Giardia lamblia, Entamoeba histolytica, and Cryptosporidium parvum. Quinfamide is thought to act by inhibiting the synthesis of DNA and RNA in protozoa. However, it has been largely replaced by newer, more effective drugs. Quinfamide is still used in some parts of the world, but its use is limited due to its potential side effects, including gastrointestinal upset and neurotoxicity. Studies of quinfamide primarily focus on its potential as a drug for treating parasitic infections, and its synthesis and structure-activity relationships. This compound is also studied for its potential to inhibit the growth of cancer cells.'

Cross-References

ID Source	ID
PubMed CID	71743
CHEMBL ID	2107014
CHEBI ID	135493
SCHEMBL ID	635943
MeSH ID	M0087079

Synonyms (46)

Synonym
einecs 263-478-1
quinfamido [inn-spanish]
quinfamidum [inn-latin]
2-furancarboxylic acid, 1-(dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinyl ester
2-furoic acid ester with 1-(dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinol
brn 1554485
win 40014
quinfamide [usan:inn]
amenide
quinfamide
1-(dichloroacetyl)-6-(2-furoyloxy)-1,2,3,4-tetrahydroquinoline
amenide (tn)
62265-68-3
D00641
quinfamide (usan/inn)
CHEBI:135493
[1-(2,2-dichloroacetyl)-3,4-dihydro-2h-quinolin-6-yl] furan-2-carboxylate
amenox
A833687
CHEMBL2107014
win-40014
unii-o1zb1046r1
o1zb1046r1 ,
quinfamido
quinfamidum
FT-0674272
SCHEMBL635943
quinfamide [inn]
quinfamide [usan]
quinfamide [who-dd]
quinfamide [mart.]
quinfamide [mi]
DTXSID90211320
AKOS030227997
1-(2,2-dichloroacetyl)-1,2,3,4-tetrahydroquinolin-6-yl furan-2-carboxylate
AS-73999
DB12780
mfcd00864662
Q21098930
BCP10697
AMY23418
EX-A3370
CS-0078079
2-furancarboxylic acid, 1-(2,2-dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinyl ester
HY-119826
quinfamida

Research Excerpts

Dosage Studied

Excerpt	Relevance	Reference
" A cure rate of 100% was found at a dosage of 100 mg/8 hr and of 93."	( A study with quinfamide in the treatment of chronic amebiasis in adults. Garcia Tsao, G; Guevara, L; Uscanga, LF, 1983)	0.64
" Previous studies demonstrated that quinfamide is a safe and efficacious drug for adult patients when given as a one-day treatment regimen of 300 mg taken in tablet form at a dosage of 100 mg every eight hours."	( Treatment of chronic amebiasis in pediatric patients with a suspension of quinfamide. Araujo Rojas, F; Benavides Ledezma, M; Gomez Garza, R; Vega Martinez, C, 1983)	0.77

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
quinolines	A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay ID	Title	Year	Journal	Article
AID1124506	Antiamebic activity against trophozoite form of Entamoeba criceti infected in hamster assessed as reduction in spontaneous infection in cecum administered intragastric gavage as single dose by microscopy	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	1-(Dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinol esters. New potent antiamebic agents.
AID1124507	Toxicity in hamster assessed as mortality at 10 mg/kg, po by acute test	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	1-(Dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinol esters. New potent antiamebic agents.
AID1124509	Antiamebic activity against Entamoeba criceti infected in hamster assessed as reduction of trophozoites in cecum administered intragastric gavage as four dose by microscopy	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	1-(Dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinol esters. New potent antiamebic agents.
AID1124505	Antiamebic activity against Entamoeba criceti infected in hamster assessed as reduction of trophozoites in cecum administered intragastric gavage bid for three consecutive days by microscopy	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	1-(Dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinol esters. New potent antiamebic agents.
AID1124508	Toxicity in rat assessed as mortality at 10 mg/kg, po by acute test	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	1-(Dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinol esters. New potent antiamebic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5 (38.46)	18.7374
1990's	2 (15.38)	18.2507
2000's	3 (23.08)	29.6817
2010's	2 (15.38)	24.3611
2020's	1 (7.69)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	36.29 (24.57)
Research Supply Index	2.94 (2.92)
Research Growth Index	4.51 (4.65)
Search Engine Demand Index	49.01 (26.88)
Search Engine Supply Index	2.09 (0.95)

This Compound (36.29)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (20.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	1 (6.67%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (73.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	4.17	3	1	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	2.15	1	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
thiazoles [no description available]	3.39	1	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	1.99	1	0	C-nitro compound; imidazoles	antitubercular agent
4-nitroimidazole 5-nitroimidazole : A C-nitro compound that is imidazole bearing a nitro substituent at position 5.	1.99	1	0	C-nitro compound; imidazoles
diloxanide furoate diloxanide furoate: structure. diloxanide furoate : A carboxylic ester resulting from the formal condensation of the carboxy group of furan-2-carboxylic acid with the hydroxy group of 2,2-dichloro-N-(4-hydroxyphenyl)-N-methylacetamide. It is a drug used for the treatment of asymptomatic amebiasis.	1.95	1	0	carboxylic ester; furans; organochlorine compound; tertiary carboxamide	antiamoebic agent; prodrug
nitazoxanide nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug	8.39	1	1	benzamides; carboxylic ester
etofamide etofamide: structure	9.05	3	1	aromatic ether

Condition	Relationship Strength	Studies	Trials
Amebiasis, Intestinal [description not available]	4.07	3	1
Colitis, Mucous [description not available]	2.15	1	0
Celiac Sprue [description not available]	2.15	1	0
Esophageal Hernia [description not available]	2.15	1	0
Malabsorption Syndromes General term for a group of MALNUTRITION syndromes caused by failure of normal INTESTINAL ABSORPTION of nutrients.	2.15	1	0
Colonic Diverticulosis [description not available]	2.15	1	0
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	2.15	1	0
Celiac Disease A malabsorption syndrome that is precipitated by the ingestion of foods containing GLUTEN, such as wheat, rye, and barley. It is characterized by INFLAMMATION of the SMALL INTESTINE, loss of MICROVILLI structure, failed INTESTINAL ABSORPTION, and MALNUTRITION.	2.15	1	0
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	2.15	1	0
Esophagitis INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.	2.15	1	0
Irritable Bowel Syndrome A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.	2.15	1	0
Infections, Nematode [description not available]	3.39	1	1
Histomoniasis [description not available]	3.39	1	1
Intestinal Diseases, Parasitic Infections of the INTESTINES with PARASITES, commonly involving PARASITIC WORMS. Infections with roundworms (NEMATODE INFECTIONS) and tapeworms (CESTODE INFECTIONS) are also known as HELMINTHIASIS.	3.39	1	1
Entamoeba histolytica Infection [description not available]	3.77	2	1
Abscess, Amebic [description not available]	2.65	3	0
Amebiasis Infection with any of various amebae. It is an asymptomatic carrier state in most individuals, but diseases ranging from chronic, mild diarrhea to fulminant dysentery may occur.	2.65	3	0
Chronic Illness [description not available]	2.36	2	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.36	2	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2	1	0

chemdatabank.com